Affiliation:
1. Fundación Quina Care Ecuador, Puerto el Carmen de Putumayo 210350, Sucumbíos, Ecuador
2. Experimental Parasitology Unit, Amsterdam University Medical Centres, Department of Medical Microbiology and Infection Prevention, Academic Medical Centre at the University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
3. Amsterdam Institute for Infection and Immunity, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Abstract
Many different animal models are in use for drug development for leishmaniasis, but a universal model does not exist. There is a plethora of models, and this review assesses their design, quality, and limitations, including the attention paid to animal welfare in the study design and execution. A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines of available literature after the year 2000 describing animal models for leishmaniasis. The risk of bias was determined using the SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) risk of bias assessment tool. A total of 10,980 records were initially identified after searching the databases PubMed, EMBASE, LILACS, and SciELO. Based on the application of predetermined exclusion and inclusion criteria, a total of 203 papers describing 216 animal experiments were available for full analysis. Major reasons for exclusion were a lack of essential study information or appropriate ethical review and approval. Mice (82.8%; an average of 35.9 animals per study) and hamsters (17.1%; an average of 7.4 animals per study) were the most frequently used animals, mostly commercially sourced, in the included studies. All studies lacked a formal sample size analysis. The promastigote stages of L. amazonensis or L. major were most frequently used to establish experimental infections (single inoculum). Animal welfare was poorly addressed in all included studies, as the definition of a human end-point or consideration of the 3Rs (Replacement, Reduction, Refinement) was hardly addressed. Most animals were euthanized at the termination of the experiment. The majority of the studies had an unknown or high risk of bias. Animal experiments for drug development for leishmaniasis mainly poorly designed and of low quality, lack appropriate ethical review, and are deficient in essential information needed to replicate and interpret the study. Importantly, aspects of animal welfare are hardly considered. This underpins the need to better consider and record the details of the study design and animal welfare.
Funder
Netherlands Organization for Health Research and Development
Subject
General Veterinary,Animal Science and Zoology
Reference33 articles.
1. Leishmaniasis;Burza;Lancet,2018
2. Leishmaniasis;Herwaldt;Lancet,1999
3. Recent advances and new strategies on leishmaniasis treatment;Roatt;Appl. Microbiol. Biotechnol.,2020
4. Social and Economic Burden of Human Leishmaniasis;Okwor;Am. J. Trop. Med. Hyg.,2016
5. Hu, R.V.P.F., Ramdas, S., Nieuwkerk, P., Reis, R., Lai AFat, R.F.M., de Vries, H.J.C., and Schallig, H.D.F.H. (2020). Body location of “New World” cutaneous leishmaniasis lesions and its impact on the quality of life of patients in Suriname. PLoS Negl. Trop. Dis., 14.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献